Stopping HIV fusion with enfuvirtide: The first step to extracellular HAART

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue 2, 2003, Pages 213-217

  Moyle, Graeme ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Fusion inhibitor; HIV

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; ENFUVIRTIDE; GLYCOPROTEIN GP 120; GROWTH HORMONE; INTERLEUKIN 2; NUCLEOSIDE DERIVATIVE; T 1249; T LYMPHOCYTE RECEPTOR;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CROSS RESISTANCE; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; DRUG TOLERABILITY; EXTRACELLULAR SPACE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION SITE; NONHUMAN; SALVAGE THERAPY; SIDE EFFECT; SUBCUTANEOUS NODULE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HUMANS; PEPTIDE FRAGMENTS;

EID: 0037323819     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg066     Document Type: Article

References (14)

1. Meynard, J. L., Vray, M., Morand-Joubert, L., Race, E., Descamps, D., Peytavin, G. et al. (2000). Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 16, 727-36.
2. Durant, J., Clevenbergh, P., Halfon, P., Delgiudice, P., Porsin, S., Simonet, P. et al. (1999). Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 353, 2195-9.
3. Baxter, J. D., Mayers, D. L., Wentworth, D. N., Neaton, J. D., Hoover, M. L., Winters, M. A. et al. (2000). A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beim Community Programs for Clinical Research on AIDS. AIDS 14, F83-93.
4. Cohen, C. J., Hunt, S., Sension, M., Farthing, C., Conant, M., Jacobson, S. et al. (2000). A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 16, 579-88.
5. Tural, C., Ruiz, L., Holtzer, C., Schapiro, J., Viciana, P., Gonzalez, J. et al. (2000). Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 16, 209-18.
6. Moyle, G. (2000). Clinical manifestations and management of antiretroviral nucleoside analogue related mitochondrial toxicity. Clinical Therapeutics 22, 911-36.
7. Kilby, J. M., Lalezari, J. P., Eron, J. J., Carlson, M., Cohen, C., Arduino, R. C. et al. (2002). The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Pesearch and Human Retroviruses 18, 685-93.
8. Lalezari, J. P., Eron, J. J., Carlson, M., Cohen, C., DeJesus, E., Arduino, R. C. et al. (2003). A Phase II clinical study of the long-term safety and antiviral activity of enfuvirtide (T-20) based antiretroviral therapy. AIDS, in press.
9. Lalezari, J., DeJesus, E., Northfelt, D., Richmond, G., Delehanty, J., DeMasi, R. et al. (2002). A week 48 assessment of a randomized, controlled, open-label phase II trial (T20-206) evaluating three doses of T-20 in P1-experienced, NNRTI-naïve patients infected with HIV-1. In Program and Abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA, 2002. Abstract 418-W. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
10. Wheat, L. J., Lalezari, J., Kilby, M., Wheeler, D., Salgo, M., DeMasi, R. et al. (2002). 48-week assessment of high strength T-20 in multi-class experienced patients. In Program and Abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA, 2002. Abstract 417-W. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
11. Henry, K., Lalezari, J., O'Hearn, M., Trottier, B., Montaner, J., Piliero, P. et al. (2002). Enfuvirtide (T-20) in combination with an optimized background (OB) regimen vs. OB alone in patients with prior experience or resistance to each of the 3 approved antiretrovirals (ARVs) in North America and Brazil (TORO 1). In Program and Abstracts of the Fourteenth International AIDS Conference, Barcelona, Spain, 2002. Abstract LBOr19B. IAS International AIDS Society, Stockholm, Sweden.
12. Clotet, B., Lazzarin, A., Cooper, D., Reynes, J., Arasteh, K., Nelson, M. et al. (2002). Enfuvirtide (T-20) in combination with an optimized background (OB) regimen vs. OB alone in patients with prior experience or resistance to each of the 3 approved antiretrovirals (ARVs) in Europe and Australia (TORO 2). In Program and Abstracts of the Fourteenth International AIDS Conference, Barcelona, Spain, 2002. Abstract LBOr19A. IAS International AIDS Society, Stockholm, Sweden.
13. Green, J., Salgo, M. P. & Delehanty, J. (2002). Patient survey on injection of enfuvirtide (T-20): ease of use and impact on activities. In Program and Abstracts of the Fourteenth International AIDS Conference, Barcelona, Spain, 2002. Abstract TuPeB4480. IAS International AIDS Society, Stockholm, Sweden.
14. Daviss, W. B., Coon, H., Whitehead, P., Ryan, K., Burkley, M. & McMahon, W. (1995). Predicting diabetic control from competence, adherence, adjustment, and psychopathology. Journal of the American Academy of Child and Adolescent Psychiatry 34, 1629-36.